Carlyle Group/Abingworth Reduces Stake Below 5% in Spruce Biosciences
Summary
The Carlyle Group and Abingworth Bioventures VII LP, a significant institutional investor, reported reducing their beneficial ownership in Spruce Biosciences, Inc. to 4.7%, falling below the 5% reporting threshold.
Key Events
-
Investor Stake Reduced
The Carlyle Group and Abingworth Bioventures VII LP now beneficially own 4.7% of Spruce Biosciences' common stock, falling below the 5% reporting threshold.
-
Director Resignation Noted
Bali Muralidhar, who represented Abingworth Bioventures VII LP, resigned from the board of directors in October 2025.
-
No Recent Transactions
The filing states no transactions were effected by the reporting persons in the past 60 days, indicating the reduction below 5% occurred earlier or through dilution.
Analysis
This Schedule 13D/A indicates that The Carlyle Group and Abingworth Bioventures VII LP, a significant institutional investor, has reduced its stake in Spruce Biosciences below the 5% beneficial ownership threshold. While no transactions were reported in the last 60 days, this reduction implies a strategic decision to decrease their investment or influence, potentially through prior sales or not participating in subsequent capital raises. This comes after the company recently announced positive clinical data and secured a significant loan, making the investor's reduced stake a notable development. The filing also notes the resignation of their representative director in October 2025, aligning with a reduced involvement.
At the time of this filing, SPRB was trading at $53.76 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $57.2M. The 52-week trading range was $4.28 to $240.00. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.